To demonstrate clinical and laboratory characteristics of Graves’ disease in human immunodeficiency virus (HIV)-infected patients on antiretroviral therapy (ART). : This is a single-institution study. All HIV-infected Thai patients who were diagnosed with Graves’ disease following initiation of ART between January 2007 and June 2018 were retrospectively enrolled. : Of the 24 subjects, the mean age was 39.6 ± 10 years at the time of Graves’ disease diagnosis. Male:female ratio was 1:1.2. Palpitation and weight loss were the most common clinical manifestations. Of the six patients (25%) with evidence of Graves’ orbitopathy, one had sight-threatening orbitopathy. Two patients also had other autoimmune diseases (vitiligo and psoriatic arthritis). The median CD4 cell counts at HIV and Graves’ disease diagnosis were 73.5 (IQR, 15.5-189.5) and 525 (IQR, 402.3-725) cells/μL, respectively. The median time from ART commencement of the last effective ART regimen to the development of Graves’ disease was 29.5 (IQR 13.8-48) months with a mean CD4 cell count increment of 328.7 ± 174.9 cells/μL. The median duration of antithyroid therapy was 34.5 (IQR 23.8-51.0) months. Thirteen 54.2%) radioactive Graves’ disease should be suspected in HIV-infected patients who present with palpitations and weight loss despite good immunological response to ART. Awareness of this condition can lead to diagnosis and appropriate management. Unlike immune reconstitution disease associated with infection, Graves’ disease may develop many years after ART initiation.
January 23, 2020
Comparison of three anti-coccidioides antibody enzyme immunoassay kits for the diagnosis of coccidioidomycosis.
April 12, 2020
Comparison of SF3B1/DNMT3A Comutations With DNMT3A or SF3B1 Mutation Alone in Myelodysplastic Syndrome and Clonal Cytopenia of Undetermined Significance.
March 2, 2020
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- CROI 2020Every year, CROI hosts some of the world's leading experts in HIV research, who come to present exciting new data and drive forward the field of HIV/AIDS research. This year, due to COVID-19, CROI held their meeting virtually.